Navigation Links
Dendreon Appoints Hans Bishop as Chief Operating Officer
Date:12/10/2009

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Hans Bishop has joined the Company as chief operating officer, effective January 4, 2010. Mr. Bishop most recently served as president of the specialty medicine business at Bayer, where he was responsible for a diverse portfolio of oncology, hematology, and neurology products. Mr. Bishop also served as an executive vice president of Bayer HealthCare LLC.

As a member of the Dendreon executive management team, Mr. Bishop will be responsible for preparing for and leading the commercial launch of PROVENGE® (sipuleucel-T), including sales and marketing, as well as manufacturing, supply chain, quality, and facilities engineering.

"Hans' extensive and successful global commercial experience will add tremendous value to Dendreon's already strong executive team as we prepare for the launch of PROVENGE in the coming year," said Mitchell H. Gold, M.D., president and chief executive officer. "Hans' deep knowledge of sales and marketing, manufacturing and operations will be integral to our success as we transform Dendreon into a commercial organization and work to fulfill our mission of transforming the lives of patients with cancer."

During his tenure leading specialty medicine at Bayer HealthCare, Mr. Bishop grew the specialty medicine business into a euro 3 billion global franchise, including overseeing the successful growth of Nexavar® and the significant expansion of the company's oncology pipeline. Prior to this position, Mr. Bishop served at Chiron Corporation as senior vice president of global commercial operations, as well as vice president and general manager of European biopharmaceuticals. In these roles, Mr. Bishop was responsible for commercial operations for the Global Biopharmaceuticals Divisi
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 PrimeSource Building Products, ... selected SoundConnect to support their communication ... audio and web conferencing platform GlobalMeet powered by ... employees’ needs. SoundConnect delivers award winning “results ... Building Products will be utilizing GlobalMeet powered ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... Plexus Corp. (Nasdaq: PLXS ) announced today ... automated screening system for the pre-processing of human papillomavirus (HPV) ... to a current manual process, through sophisticated robotic motions. ... HPV; a virus that has an established link to cervical ...
... general health and self-care management by using simple tools ... May 28 Roche, the maker of ACCU-CHEK(R) blood ... availability of two new tools that can help patients ... impact on their blood glucose levels, giving them greater ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
Cached Biology Technology:Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 2Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 3SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... America,s 27th Annual Mouse Molecular Genetics Conference from ... Grove, California. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the Genetics Society ...
(Date:8/28/2014)... delivering compounds that could positively impact the ... be possible, thanks to researchers in Penn ... vaginal suppository made from the seaweed-derived food ... drug Tenofovir provides a woman-initiated, drug-delivery vehicle ... sexually transmitted infections during unprotected heterosexual intercourse, ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... scientists from the National Human Genome Research Institute (NHGRI), ... reported it has identified six more genetic variants involved ... number of genetic risk factors associated with increased risk ... by the new study had previously been suspected of ...
... crosses between nerve cells. Changes in the strength of ... both memory formation and learning, and help determine how ... Dubnau, Ph.D., leads a CSHL neuroscience lab that studies ... team had previously identified a group of fly genes ...
... -Oceanic shark populations worldwide are declining from destructive high-seas ... shark products (mainly fins and meat), with some shark ... recovering, according to a comprehensive new book co-edited by ... ( www.pewoceanscience.org ), published by Blackwell Publishing, and being ...
Cached Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists identify a mechanism that helps fruit flies lock-in memories 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 3Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 4
...
...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: